secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056782
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR
--------------------------------------------------------------------------------

- Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
- FY 2026 revenue guidance $350-$370M; Q2 2026 guidance $86-$88M.
- Lifileucel in metastatic serous endometrial cancer: 40% confirmed ORR, 100% DCR in first 5 patients; FDA expedited path planned.
- Cash ~$319M, expected to fund operations into 2028; R&D expenses down 12% vs Q4 2025.
- UK MAA for lifileucel withdrawn for procedural reasons, will resubmit; EMA resubmission planned for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/0001104659-26-056782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer